[en] BACKGROUND: Outcome of sirolimus-eluting stent (SES) in patients treated with an antivitamin K (VKA) agent before the PCI procedure is unknown. METHODS: A total of 7651 patients were selected among 15,147 recipients of SES, included in the worldwide e-SELECT registry, only from those centers which included at least one patient requiring VKA: 296 were pretreated with a VKA agent (VKA group), whereas 7355 patients from the same enrolling medical centers were not (NON-VKA group). The rates of 1) major adverse cardiac events (MACE), including all-cause deaths, myocardial infarction (MI) and target lesion revascularization, 2) stent thrombosis (ST) and 3) major bleeding (MB) in the 2 study groups were compared at 1, 6 and 12 months. RESULTS: The patients in VKA group were on average older as compared to those in NON-VKA group (67.7 +/- 9.9 vs.62.9 +/- 10.7, P<0.001). The indications for pre-procedural anticoagulation were atrial fibrillation in 177 (59.8%), presence of a prosthetic valve in 21 (7.1%), embolization of cardiac origin in 17 (5.7%), pulmonary embolism or deep vein thrombosis in 17 (5.7%), and miscellaneous diagnoses in 64 (21.6%) patients. At 1 year, the rates of MACE and MB were higher in the VKA vs. the NON-VKA group (8.3% and 3% vs. 5.3% and 1.2%, P<0.04 and P<0.002, respectively). The 1-year rates of definite and probable ST were remarkably low in both groups (0.38% vs. 1.1%, p=0.4). CONCLUSIONS: Selected patients anticoagulated with VKA agent may safely undergo SES implantation. Those patients may receive a variety of APT regimen at the cost of a moderate increased risk of MB.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Sabate, Manel
Brugaletta, Salvatore
Abizaid, Alexandre
Banning, Adrian
Bartorelli, Antonio
Dzavik, Vladimir
Ellis, Stephen
Holmes, David
Gao, Runlin
Jeong, Myung Ho
Legrand, Victor ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie
P. Urban, A.H. Gershlick, and G. Guagliumi Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry Circulation 113 2006 1434 1441
G.Y. Lip, K. Huber, and F. Andreotti Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary - a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J 31 2010 1311 1318
D.P. Faxon, J.W. Eikelboom, and P.B. Berger Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective Thromb Haemost 106 2011 572 584
P. Urban, A. Abizaid, and A. Banning Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population: a report from the e-SELECT (Multi-Center Post-Market Surveillance) registry J Am Coll Cardiol 57 2011 1445 1454
D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
G. Montalescot, H.D. White, and R. Gallo Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention N Engl J Med 355 2006 1006 1017
R. Rogacka, A. Chieffo, and I. Michev Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation JACC Cardiovasc Interv 1 2008 56 61
J.M. Ruiz-Nodar, F. Marin, and J.A. Hurtado Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis J Am Coll Cardiol 51 2008 818 825
V. Martin-Yuste, S. Brugaletta, and I. Ferreira-Gonzalez Endothelial progenitor cell capturing stent and short dual antiplatelet therapy in patients on chronic anti-vitamin k regimen undergoing percutaneous coronary interventions: long-term outcomes of a single centre registry EuroIntervention 6 2011 831 837
P.P. Karjalainen, P. Porela, and A. Ylitalo Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting Eur Heart J 28 2007 726 732
P.P. Karjalainen, S. Vikman, and M. Niemela Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment Eur Heart J 29 2008 1001 1010
J.L. Navarro, J.M. Cesar, M.A. Fernandez, J. Fontcuberta, J.C. Reverter, and J. Gol-Freixa Morbidity and mortality in patients treated with oral anticoagulants Rev Esp Cardiol 60 2007 1226 1232
J.M. Ruiz-Nodar, F. Marin, and J. Sanchez-Paya Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation Eur Heart J 30 2009 932 939
M.C. Morice, P.W. Serruys, and J.E. Sousa A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 346 2002 1773 1780
H.J. Colmenarez, J. Escaned, and C. Fernandez Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization: a systematic review and meta-analysis J Am Coll Cardiol 55 2010 1854 1866
F. Alfonso, J. Garcia, and M.J. Perez-Vizcayno New stent implantation for recurrences after stenting for in-stent restenosis: implications of a third metal layer in human coronary arteries J Am Coll Cardiol 54 2009 1036 1038
M. Sabate, P. Jimenez-Quevedo, and D.J. Angiolillo Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial Circulation 112 2005 2175 2183
Y.J. Hong, M.H. Jeong, and A. Abizaid Sirolimus-eluting coronary stents in octogenarians: a 1-year analysis of the worldwide e-SELECT Registry JACC Cardiovasc Interv 4 2011 982 991
A. de Waha, A. Dibra, and R.A. Byrne Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials Circ Cardiovasc Interv 4 2011 371 377
K.W. Park, I.H. Chae, and D.S. Lim Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial J Am Coll Cardiol 58 2011 1844 1854
E. Camenzind, W. Wijns, and L. Mauri Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial Lancet 380 2012 1396 1405
F. Gao, Y.J. Zhou, and Z.J. Wang Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation Int J Cardiol 148 2011 96 101
J.M. Ruiz-Nodar, F. Marin, and V. Roldan Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? Circ Cardiovasc Interv 5 2012 459 466
C.B. Granger, J.H. Alexander, and J.J. McMurray Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
G.Y. Lip, K. Huber, and F. Andreotti Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting Thromb Haemost 103 2010 13 28
B. Dewilde Omission of aspirin from antiplatelet regimen reduces incidence of bleeding without compromising safety in patients taking oral anticoagulants and having coronary stent placement: the WOEST study Hot Line III: Late breaking trials 2012 2012 ESC
